SCHEMBL6322509

SCHEMBL6322509

Brc1cccc(-c2cccc3[nH]ccc23)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ASH1L Q9NR48 1/20 0.59
▸ PIK3CD O00329 3/20 0.56
▸ PIK3CB P42338 2/20 0.52
▸ CSNK1D P48730 1/20 0.52
▸ AHR P35869 2/20 0.52
▸ PIK3CG P48736 1/20 0.51
▸ MAPK14 Q16539 4/20 0.51
▸ CAMK2D Q13557 1/20 0.49
▸ CSNK2B P67870 1/20 0.48
▸ CSNK2A1 P68400 1/20 0.48
▸ CHEK1 O14757 1/20 0.44
▸ PIP4K2A P48426 1/20 0.41
▸ PIP4K2B P78356 1/20 0.41
▸ PIP4K2C Q8TBX8 1/20 0.41
▸ HPGDS O60760 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ METAP2 P50579 1/20 0.40
▸ FTO Q9C0B1 1/20 0.40
▸ ATM Q13315 1/20 0.39
▸ ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10945814 0.83 PIK3CD (0.75) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL6322061 0.82 PIK3CD (0.64) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL6321711 0.81 ASH1L (0.60) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL29712113 0.80 PIK3CD (0.70) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL2193011 0.80 PIK3CD (0.70) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL23259083 0.79 ASH1L (0.59) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL6321811 0.79 CSNK2B (0.62) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL6322388 0.79 ASH1L (0.59) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL982028 0.79 ASH1L (0.63) ASH1LPIK3CDPIK3CBAHRPIK3CG
SCHEMBL1129041 0.78 PIK3CD (0.51) ASH1LPIK3CDPIK3CBAHRPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 — — US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 — — US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 — — US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 — — EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 — — US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ASH1L 1883/4885PIK3CD 365/4885PIK3CB 275/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ASH1L 1883/4885PIK3CD 365/4885PIK3CB 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback